Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM), a clinical-stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announces that Mr. Darren Lui, CEO and Executive Director of Atorum Group, will present in person and virtually at the HC Wainwright Global Investment Conference, taking place September 13-16, 2022 in New York.
Atorum Group management will be available and will host face-to-face and online meetings with institutional investors throughout the conference. To register for the conference, go to: https://hcwevents.com/annualconference/.
About Aptorum Group
Atorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic agents to address unmet medical needs, particularly in oncology (including orphan oncological indications), autoimmune diseases and infectious diseases. Aptorum has completed two Phase I clinical trials for its small molecule drugs ALS-4 (SDMR) and SACT-1 (neuroblastoma) designated orphan drug, and the marketing of its nutraceutical agent NLS-2 Nativuswell (menopause). Aptorum’s portfolio of projects is also enriched by (i) the establishment of drug discovery platforms that enable the discovery of new therapeutic actives, in particular through systematic screening of existing approved drug molecules, and a microbiome-based research platform for the treatment of metabolic diseases; and (ii) the ongoing co-development and clinical validation of its new molecular rapid diagnostic technology for pathogen identification and detection with the Commercial Division of the Singapore Science, Technology and Research Agency.
For more information about the company, visit www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or a solicitation of offers to buy securities of Atorum Group.
This press release includes statements relating to Atorum Group Limited and its expectations, prospects and future plans, which constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In this respect, the statements contained in this press release that are not statements of past fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “could”, “should”, “expect”, “plan”, “anticipate”, “intend”, “target “, “plans”, “intends”, “believes”, “estimates”, “predicts”, “potential” or “continues”, or the negative form of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements relating to expected timelines for application submissions and trials, primarily on its current expectations and projections of future trends and events that the company believes are likely to occur. have an impact on its activity, its financial situation and the results of its operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, but not limited to, risks relating to the announced changes in the levels management and organization, the retention and availability of key personnel, the company’s ability to expand its product lines by offering additional products in other consumer segments, the results of its development activities, the company’s anticipated growth strategies, anticipated trends and challenges in its business, its expectations for and stability of its supply chain, the risks detailed on the Form 20-F of Aptorum Group and other filings that Aptorum Group may file with the SEC in the future, as well as in the prospectus received by the Autorité des Marchés Financiers, visa n°20-352, on July 16, 2020. Accordingly , the The expectations contained in such forward-looking statements are subject to change and actual results could differ materially from those described herein.
Atorum Group undertakes no obligation to update any forward-looking statements contained in this press release, whether in light of new information, future events or otherwise.
This press release does not constitute a prospectus within the meaning of Regulation (EU) No. 2017/1129 of June 14, 2017 as amended by Delegated Regulations (EU) No. 2019/980 of March 14, 2019 and No. March 2019.
This press release is provided as is, without any representations or warranties of any kind.
The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared with the source text, which will set a precedent.
View the source version on businesswire.com: https://www.businesswire.com/news/home/20220825005367/en/